Recent advances in targeted cancer therapies have led to the development of small molecule inhibitors designed to address oncogenic RAS gene mutations, particularly regarding KRAS, which is the most frequently mutated RAS isoforms in human cancers [76,84]. This evidence concerns the gene KRAS and cancer.